Drug
Ganaxolone clinical trials
Also written CCD 1042.
- studies test it
- 24
- open now
- 2
- in phase 3
- 8
- first study started
- 2007
Keep track of what changes. Save the ganaxolone studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
- gnx
- 2
Development codes
Studies by the year they started
22 studies that test it; most in 2007 (4); 2 more planned to start later
| Year | Studies |
|---|---|
| 2007 | 4 |
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 15
- Phase 3
- 8
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 21 · Other 3
Marinus Pharmaceuticals (20) · Massachusetts General Hospital (1) · Jed E. Rose (1) · Immedica Pharma AB (1) · Stanford University (1)
Studies
Open first, then newest update. How each study uses ganaxolone is read from its arms, and is right about nine times in ten.
Testing it · 24
- Double-blind, Randomized, Placebo-controlled Trial of Ganaxolone in CDKL5 Deficiency Patients 6 Months to Less Than 2 Years OldNot yet recruitingPhase 3Immedica Pharma ABNCT05249556Written as Ganaxolone
- Clinical Trial Evaluating the Effects of Ganaxolone in Children With AutismNot yet recruitingPhase 2Stanford UniversityNCT07635862Written as Ganaxolone (Ztalmy)
- Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related EpilepsyTerminatedPhase 3Marinus PharmaceuticalsNCT05604170Written as Ganaxolone
- Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related EpilepsyCompletedPhase 3Marinus PharmaceuticalsNCT05323734Written as Ganaxolone
- Randomized Therapy In Status EpilepticusCompletedPhase 3Marinus PharmaceuticalsNCT04391569Written as Ganaxolone
- Open-label Extension to Protocol 1042-0500TerminatedPhase 2Marinus PharmaceuticalsNCT00442104Written as Ganaxolone
- To Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ganaxolone Added to Standard of Care in Refractory Status Epilepticus (RSE)WithdrawnPhase 3Marinus PharmaceuticalsNCT05814523Written as Ganaxolone
- Safety and Efficacy Study of IV Ganaxolone as Adjuvant Therapy for Established Status Epilepticus (ESE)WithdrawnPhase 2Marinus PharmaceuticalsNCT05757544Written as IV Ganaxolone
- A Clinical Trial of Oral Ganaxolone in Women With Postpartum DepressionCompletedPhase 2Marinus PharmaceuticalsNCT03460756Written as Ganaxolone
- A Clinical Trial of Intravenous (IV) Ganaxolone in Women With Postpartum DepressionCompletedPhase 2Marinus PharmaceuticalsNCT03228394Written as Ganaxolone
- A Two-year Open-label Extension Study of Ganaxolone in Patients With Drug-resistant Partial-onset SeizuresTerminatedPhase 3Marinus PharmaceuticalsNCT02519439Written as ganaxolone
- Study of Adjunctive Ganaxolone Treatment in Female Children With Protocadherin 19 (PCDH19)-Related Epilepsy (Violet Study)CompletedPhase 2Marinus PharmaceuticalsNCT03865732Written as Ganaxolone
- A Randomized, Controlled Trial of Ganaxolone in Patients With Infantile SpasmsCompletedPhase 2Marinus PharmaceuticalsNCT00441896Written as Ganaxolone
- Study of Adjunctive Ganaxolone Treatment in Children and Young Adults With CDKL5 Deficiency DisorderCompletedPhase 3Marinus PharmaceuticalsNCT03572933Written as ganaxolone
- Ganaxolone Treatment in Children With Fragile X SyndromeCompletedPhase 2Marinus PharmaceuticalsNCT01725152Written as Ganaxolone
- Adjunctive Ganaxolone Treatment (Part A) in TSC Followed by Long-term Treatment (Part B)CompletedPhase 2Marinus PharmaceuticalsNCT04285346Written as Ganaxolone
- Open-Label PoC Trial of Ganaxolone in Children With PCDH19 Female Pediatric Epilepsy and Other Rare Genetic EpilepsiesCompletedPhase 2Marinus PharmaceuticalsNCT02358538Written as Ganaxolone
- A Randomized, Controlled Trial of Ganaxolone in Adult Uncontrolled Partial-Onset SeizuresCompletedPhase 2Marinus PharmaceuticalsNCT00465517Written as Ganaxolone
- Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label ExtensionCompletedPhase 3Marinus PharmaceuticalsNCT01963208Written as ganaxolone
- Open-label Extension to Protocol 1042-0600CompletedPhase 2Marinus PharmaceuticalsNCT00512317Written as ganaxolone
Codes
What other systems call ganaxolone · ClinicalTrials.gg INT003973
- MeSH (NLM) C105051ganaxoloneConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 98WI44OHIQGANAXOLONEConfirmed FDA, NLM, Wikidata
- RxNorm 2604689One source FDA
- Wikidata Q3758034ganaxoloneConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C72793GanaxoloneOne source FDA
- DrugBank DB05087One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C105051 | ganaxolone | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 98WI44OHIQ | GANAXOLONE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2604689 | — | One source FDA |
| Wikidata | Q3758034 | ganaxolone | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C72793 | Ganaxolone | One source FDA |
| DrugBank | DB05087 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.